Literature DB >> 34904809

PARP Inhibitors in Pancreatic Cancer.

Timothy J Brown1, Kim A Reiss.   

Abstract

ABSTRACT: Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34904809      PMCID： PMC8682800          DOI： 10.1097/PPO.0000000000000554

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  90 in total

Review 1.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination.

Authors:  Pedro A Mateos-Gomez; Fade Gong; Nidhi Nair; Kyle M Miller; Eros Lazzerini-Denchi; Agnel Sfeir
Journal:  Nature       Date:  2015-02-02       Impact factor: 49.962

3.  Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Authors:  Junko Murai; Shar-Yin N Huang; Amèlie Renaud; Yiping Zhang; Jiuping Ji; Shunichi Takeda; Joel Morris; Beverly Teicher; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

4.  Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.

Authors:  Talia Golan; Grainne M O'Kane; Robert E Denroche; Maria Raitses-Gurevich; Robert C Grant; Spring Holter; Yifan Wang; Amy Zhang; Gun Ho Jang; Chani Stossel; Dikla Atias; Sharon Halperin; Raanan Berger; Yulia Glick; J Patrick Park; Adeline Cuggia; Laura Williamson; Hui-Li Wong; David F Schaeffer; Daniel J Renouf; Ayelet Borgida; Anna Dodd; Julie M Wilson; Sandra E Fischer; Faiyaz Notta; Jennifer J Knox; George Zogopoulos; Steven Gallinger
Journal:  Gastroenterology       Date:  2021-01-30       Impact factor: 22.682

5.  Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

Authors:  Eileen M O'Reilly; Jonathan W Lee; Maeve A Lowery; Marinela Capanu; Zsofia K Stadler; Malcolm J Moore; Neesha Dhani; Hedy L Kindler; Hayley Estrella; Hannah Maynard; Talia Golan; Amiel Segal; Erin E Salo-Mullen; Kenneth H Yu; Andrew S Epstein; Michal Segal; Robin Brenner; Richard K Do; Alice P Chen; Laura H Tang; David P Kelsen
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

6.  ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.

Authors:  Aparajitha Vaidyanathan; Lynne Sawers; Anne-Louise Gannon; Probir Chakravarty; Alison L Scott; Susan E Bray; Michelle J Ferguson; Gillian Smith
Journal:  Br J Cancer       Date:  2016-07-14       Impact factor: 7.640

7.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann
Journal:  Lancet       Date:  2017-09-12       Impact factor: 79.321

8.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Guilhem Roubaud; Mustafa Özgüroğlu; Jinyu Kang; Joseph Burgents; Christopher Gresty; Claire Corcoran; Carrie A Adelman; Johann de Bono
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 91.245

9.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Authors:  C Cruz; M Castroviejo-Bermejo; S Gutiérrez-Enríquez; A Llop-Guevara; Y H Ibrahim; A Gris-Oliver; S Bonache; B Morancho; A Bruna; O M Rueda; Z Lai; U M Polanska; G N Jones; P Kristel; L de Bustos; M Guzman; O Rodríguez; J Grueso; G Montalban; G Caratú; F Mancuso; R Fasani; J Jiménez; W J Howat; B Dougherty; A Vivancos; P Nuciforo; X Serres-Créixams; I T Rubio; A Oaknin; E Cadogan; J C Barrett; C Caldas; J Baselga; C Saura; J Cortés; J Arribas; J Jonkers; O Díez; M J O'Connor; J Balmaña; V Serra
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

10.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

Authors:  Wassim Abida; Akash Patnaik; David Campbell; Jeremy Shapiro; Alan H Bryce; Ray McDermott; Brieuc Sautois; Nicholas J Vogelzang; Richard M Bambury; Eric Voog; Jingsong Zhang; Josep M Piulats; Charles J Ryan; Axel S Merseburger; Gedske Daugaard; Axel Heidenreich; Karim Fizazi; Celestia S Higano; Laurence E Krieger; Cora N Sternberg; Simon P Watkins; Darrin Despain; Andrew D Simmons; Andrea Loehr; Melanie Dowson; Tony Golsorkhi; Simon Chowdhury
Journal:  J Clin Oncol       Date:  2020-08-14       Impact factor: 44.544
View more
  2 in total

1.  A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).

Authors:  Martha E Teke; Areeba Saif; Carrie E Ryan; Stephanie C Lux; Jonathan M Hernandez; Kim A Reiss
Journal:  Ann Surg Oncol       Date:  2022-06-06       Impact factor: 4.339

Review 2.  The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.

Authors:  Congqi Shi; Kaiyu Qin; Anqi Lin; Aimin Jiang; Quan Cheng; Zaoqu Liu; Jian Zhang; Peng Luo
Journal:  J Exp Clin Cancer Res       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.